Lantus®

DRUG12 trials

Sponsors

Sanofi, Wockhardt, Mylan Inc., Eli Lilly and Company, Adocia

Conditions

Clamp StudyDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Type 1 DiabetesType 1 Diabetes MellitusType 2 DiabetesType 2 Diabetes MellitusType I Diabetes

Phase 1

A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

CompletedNCT02915250

AdociaType 2 Diabetes Mellitus

Start: 2016-10-31End: 2017-06-30Updated: 2017-06-29

Phase 3

Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients

WithdrawnNCT01352663

WockhardtType I Diabetes

Updated: 2019-10-08

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

CompletedNCT02227862

Mylan Inc.Type 1 Diabetes

Start: 2014-06-30End: 2016-07-31Updated: 2022-03-03

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)

CompletedNCT02227875

Mylan Inc.Type 2 Diabetes

Start: 2014-08-31End: 2015-12-31Updated: 2022-03-03

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

CompletedNCT02302716

Eli Lilly and CompanyDiabetes Mellitus, Type 2

Start: 2014-12-31End: 2016-07-31Updated: 2017-10-24

Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients

CompletedNCT02666430

Mylan Inc.Type 1 Diabetes Mellitus

Start: 2015-12-31End: 2017-07-31Updated: 2022-03-03

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus

CompletedNCT03338023

Eli Lilly and CompanyType 1 Diabetes

Start: 2018-03-23End: 2020-03-05Updated: 2021-03-29

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus

CompletedNCT03338010

Eli Lilly and CompanyType 2 Diabetes

Start: 2018-03-22End: 2020-03-18Updated: 2021-05-25

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

CompletedNCT03371108

Gan and Lee Pharmaceuticals, USADiabetes Mellitus, Type 2

Start: 2017-10-31End: 2019-04-17Updated: 2022-04-01

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

CompletedNCT03371082

Gan and Lee Pharmaceuticals, USADiabetes Mellitus, Type 1

Start: 2017-10-31End: 2019-08-19Updated: 2024-05-14

Phase 4

Glycemic Optimization Treatment Study

CompletedNCT00552370

SanofiDiabetes Mellitus, Type 2

Start: 2003-03-31End: 2005-03-31Updated: 2009-07-21

Unknown Phase

A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients

CompletedNCT04101383

GeropharmClamp Study

Start: 2017-10-16End: 2018-02-16Updated: 2019-09-24

Related Papers

Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus<sup>®</sup>): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial.

2022-04-262 citations

Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies.

2021-06-262 citations

Lilly Insulin Glargine Versus Lantus® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study

Clinical Drug Investigation2019-05-222 citations

Lilly Insulin Glargine Versus Lantus<sup>®</sup> in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5).

2019-01-0214 citations